论文部分内容阅读
目的:探讨肝炎后肝硬化并发门脉高压患者载脂蛋白AⅠ(ApoAⅠ)和载脂蛋白B100(ApoB100)水平的临床意义。方法:肝炎后肝硬化并发门脉高压患者和正常对照组各48例,空腹12h后,收集其清晨静脉血2ml,采用HITACHI7180A型全自动生化分析仪,分别测定血清ApoAⅠ、ApoB100水平。结果:患者ApoAⅠ和ApoB100水平较对照组检测结果显著下降(P<0.01)。结论:ApoAⅠ、ApoB100的水平变化可以较准确反应肝炎后肝硬化并发门脉高压患者的肝细胞受损的严重程度,可作为判断其病变及预后的辅助手段。
Objective: To investigate the clinical significance of the levels of apolipoprotein A (ApoAⅠ) and apolipoprotein B100 (ApoB100) in patients with posthepatitic cirrhosis complicated with portal hypertension. Methods: Forty-eight patients with posthepatitic cirrhosis complicated with portal hypertension and normal control group were randomly divided into two groups: early morning venous blood (2 ml) was collected after fasting for 12 hours and serum levels of ApoAⅠ and ApoB100 were measured by HITACHI 7180A automatic biochemical analyzer. Results: The levels of ApoAⅠ and ApoB100 in patients were significantly lower than those in control group (P <0.01). Conclusion: The changes of ApoAⅠ and ApoB100 can reflect the severity of hepatocellular damage in patients with posthepatitic cirrhosis and portal hypertension more accurately, which can be used as an adjunct to judge the pathological changes and prognosis.